• Coloplast’s Nov. 3, 2026, fourth-quarter earnings call featured CEO Gavin Wood and CFO Anders Lonning-Skovgaard, with analysts participating.
• Management revised ambitions through fiscal 2029/30 to annual organic growth of 5%-7% and an EBIT margin in the mid-20s at constant currencies.
• The revision reflects healthcare pricing pressure, US outpatient Biologics reimbursement changes and increased investment in innovation and US growth.
• Fiscal 2026/27 guidance targets organic revenue growth of 5%-7% and an EBIT margin around 25%, with improvement expected from the second quarter.
• The resource-reallocation program targets DKK 500 million, with approximately 80% earmarked for stepped-up investments and full benefits expected in fiscal 2027/28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coloplast A/S published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.